Document Detail


Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition.
MedLine Citation:
PMID:  11441907     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Urotensin II (U-II) is a cyclic peptide, recently cloned in man and present in cardiac tissue and arteries. The effects of human U-II (hU-II) on coronary perfusion pressure (CPP) were investigated in isolated rat hearts perfused retrogradely via the aorta at constant flow. hU-II produced a concentration-dependent increase in CPP (pEC50 8.6 +/- 0.3, n = 8), the maximum increase in CPP (12 +/- 4 mmHg) was obtained at 10(-7) M hU-II. At higher concentrations of hU-II CPP fell back towards baseline. Endothelin-1 produced a maximum increase in CPP of 63 +/- 11 mmHg within the concentration-range studied. Addition of the NO synthase inhibitor L N(G)nitro-arginine methyl ester (10(-4) M) and the cyclooxygenase inhibitor, indomethacin (10(-5) M) to the perfusion solution had no effect on the pEC50 value for hU-II, but significantly increased the maximum constriction (to 34 +/- 7 mmHg, n = 8, p < 0.05) and inhibited the later dilator response to hU-II. These results suggest that receptors for hU-II are present in the coronary vasculature and that smooth muscle contraction is modulated by the release of dilator factors, including NO and prostacyclin. Endothelial function is therefore likely to be of primary importance in modulating the coronary vasoconstrictor effects of hU-II in vivo.
Authors:
G A Gray; M R Jones; I Sharif
Related Documents :
1697367 - Hemodynamic effects of a kinin antagonist.
7165847 - Vascular reactivity during the development of two-kidney, one-clip goldblatt hypertensi...
16667097 - Osmotic pressure of aqueous polyethylene glycols : relationship between molecular weigh...
23494677 - Two cases in which the effectiveness of "laryngospasm notch" pressure against laryngosp...
9845297 - The dependence of hepatic function upon sufficient oxygen supply during prolonged isola...
16548897 - Obstructive sleep apnoea syndrome: translating science to clinical practice.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Life sciences     Volume:  69     ISSN:  0024-3205     ISO Abbreviation:  Life Sci.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-07-09     Completed Date:  2001-07-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375521     Medline TA:  Life Sci     Country:  England    
Other Details:
Languages:  eng     Pagination:  175-80     Citation Subset:  IM    
Affiliation:
Centre for Cardiovascular Science, University of Edinburgh, Dept of Biomedical Sciences, Scotland, UK. gillian.gray@ed.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Pressure / drug effects*,  physiology
Cardiovascular Agents / pharmacology
Coronary Circulation / drug effects*,  physiology
Endothelin-1 / pharmacology
Enzyme Inhibitors / pharmacology
Humans
Indomethacin / pharmacology
Male
NG-Nitroarginine Methyl Ester / pharmacology
Perfusion
Rats
Rats, Sprague-Dawley
Urotensins / metabolism,  pharmacology*
Vasoconstrictor Agents / metabolism,  pharmacology*
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 0/Endothelin-1; 0/Enzyme Inhibitors; 0/Urotensins; 0/Vasoconstrictor Agents; 50903-99-6/NG-Nitroarginine Methyl Ester; 53-86-1/Indomethacin; 9047-55-6/urotensin II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Central and peripheral catecholamines regulate the exercise-induced elevation of plasma interleukin ...
Next Document:  Effect of St. John's wort on free radical production.